scholarly journals Longitudinal evaluation of azithromycin and cytokine concentrations in amniotic fluid following one‐time oral dosing in pregnancy

2021 ◽  
Author(s):  
Rupsa C. Boelig ◽  
Edwin Lam ◽  
Ankit Rochani ◽  
Gagan Kaushal ◽  
Amanda Roman ◽  
...  
Keyword(s):  
Amniotic Fluid ◽  
Longitudinal Evaluation ◽  
Oral Dosing ◽  
In Pregnancy

scholarly journals LB20. Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S1002-S1002 ◽  
Author(s):  
Keren Shahar-Nissan ◽  
Joseph Pardo ◽  
Orit Peled ◽  
Irit Krause ◽  
Efraim Bilavsky ◽  
...  
Keyword(s):  
Amniotic Fluid ◽  
Vertical Transmission ◽  
Primary Infection ◽  
Antiviral Drug ◽  
First Trimester ◽  
Controlled Study ◽  
Therapeutic Drug ◽  
Control Group ◽  
Cmv Infection ◽  
In Pregnancy

Abstract Background Cytomegalovirus (CMV) is the most common cause of congenital infection in humans. The highest risk of fetal injury follows a maternal primary infection early in pregnancy. Despite the potential for severe fetal injury, to date there are no proven means to prevent viral transmission. Valacyclovir is an antiviral drug proven effective in decreasing the risk for CMV infection among transplant recipients. Valacyclovir is safe for use in pregnancy, and concentrates in the amniotic fluid without accumulating. A dose of 8 g/day creates therapeutic drug levels in the amniotic fluid and fetal blood. Methods This is a randomized, double-blind, placebo-controlled study comprising pregnant women with serologic evidence of primary CMV infection during the periconceptional period and first trimester. After informed consent, patients were randomly assigned to a treatment group (8 g/day of Valacyclovir) or control group (placebo). Treatment was initiated at the time of serological detection, and continued until amniocentesis. The primary endpoint was the rate of vertical transmission of CMV—determined by amniotic fluid CMV PCR. Secondary endpoints included evidence of symptomatic congenital CMV infection—in utero or postnatally. Results One hundred women were recruited, 90 were included in the data analysis; 45 patients received Valacyclovir and 45 placebo. There were 2 twin pregnancies, and therefore 92 amniocentesis Amongst the Valacyclovir group, 5 (11.1%) amniocentesis were positive for CMV, compared with 14 (29.8%) in the placebo group (P GLMM = 0.03), corresponding with an odds ratio of 0.29 (95% CI: 0.09–0.90) for vertical CMV transmission. Amongst patients infected during the first trimester, a positive amniocentesis for CMV was significantly (P = 0.02) less likely in the Valacyclovir arm (2/19) compared with placebo (11/23). No significant differences (P = 0.91) in CMV-positive amniocentesis were observed between study arms amongst patients infected periconceptionally. Conclusion Valacyclovir at a dose of 8 g/day is effective in reducing the rate of fetal CMV infection following early maternal primary infection during pregnancy. The drug reduces the rate of fetal infection by 71%. Disclosures All authors: No reported disclosures.

scholarly journals Amniotic Fluid Embolism- A Catastrophic Syndrome in Pregnancy

2019 ◽  
Vol 8 (40) ◽  
pp. 3050-3051
Author(s):  
Swati M. Patel ◽  
Kunur Shah ◽  
Mukesh Patel
Keyword(s):  
Amniotic Fluid ◽  
Amniotic Fluid Embolism ◽  
In Pregnancy

LIF analysis of cervical mucus and amniotic fluid for maturity monitoring in pregnancy

2004 ◽  
Author(s):  
Aurelija Vaitkuviene ◽  
Egidijus Auksorius ◽  
Diana Ramasauskaite ◽  
Ale Smilgeviciute ◽  
Oldas Tamasauskas ◽  
...  
Keyword(s):  
Amniotic Fluid ◽  
Cervical Mucus ◽  
In Pregnancy

The effect of gestational age on amniotic fluid glucose in pregnancy complicated by diabetes mellitus

1982 ◽  
Vol 142 (5) ◽  
pp. 492-496 ◽  
Author(s):  
Sharon L. Dooley ◽  
Boyd E. Metzger ◽  
Richard Depp ◽  
Norbert Freinkel ◽  
Richard L. Phelps
Keyword(s):  
Diabetes Mellitus ◽  
Amniotic Fluid ◽  
Gestational Age ◽  
In Pregnancy

Lamotrigine in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood

2015 ◽  
Vol 30 (5) ◽  
pp. 249-254 ◽  
Author(s):  
Michael Paulzen ◽  
Sarah E. Lammertz ◽  
Tanja Veselinovic ◽  
Tamme W. Goecke ◽  
Christoph Hiemke ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Amniotic Fluid ◽  
Cord Blood ◽  
Drug Monitoring ◽  
Maternal Blood ◽  
Therapeutic Drug ◽  
In Pregnancy

Sertraline in pregnancy – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood

2017 ◽  
Vol 212 ◽  
pp. 1-6 ◽  
Author(s):  
Michael Paulzen ◽  
Tamme W. Goecke ◽  
Elmar Stickeler ◽  
Gerhard Gründer ◽  
Georgios Schoretsanitis
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Amniotic Fluid ◽  
Cord Blood ◽  
Drug Monitoring ◽  
Maternal Blood ◽  
Therapeutic Drug ◽  
In Pregnancy

Composition of the amniotic fluid and maternal serum in pregnancy

1974 ◽  
Vol 119 (6) ◽  
pp. 798-810 ◽  
Author(s):  
R.J. Benzie ◽  
T.A. Doran ◽  
J.L. Harkins ◽  
V.M. Jones Owen ◽  
C.J. Porter
Keyword(s):  
Amniotic Fluid ◽  
Maternal Serum ◽  
In Pregnancy

Estriol in pregnancy urine and amniotic fluid

1966 ◽  
Vol 95 (3) ◽  
pp. 301-307 ◽  
Author(s):  
Adolf E. Schindler ◽  
Walter L. Herrmann
Keyword(s):  
Amniotic Fluid ◽  
Pregnancy Urine ◽  
In Pregnancy

Amniotic Fluid Index and Mean Diastolic Maternal Blood Pressure in Pregnancy-Induced Hypertensive Patients

1996 ◽  
Vol 15 (2) ◽  
pp. 219-228
Author(s):  
Herbert Valensise ◽  
Raffaele Conforti ◽  
Dario Cipriani ◽  
Donatella Dell'anna ◽  
Alessandra Petruio ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Amniotic Fluid ◽  
Maternal Blood ◽  
Amniotic Fluid Index ◽  
Hypertensive Patients ◽  
Maternal Blood Pressure ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document